Artikel ; Online: First-line cetuximab + platinum-based therapy for recurrent/metastatic head and neck squamous cell carcinoma: A real-world observational study-ENCORE.
Cancer reports (Hoboken, N.J.)
2023 Band 6, Heft 5, Seite(n) e1804
Abstract: Background: ENCORE, an observational, prospective, open-label study, investigated real-world treatment practices and outcomes with cetuximab plus platinum-based therapy (PBT) in first-line (1L) recurrent and/or metastatic squamous cell carcinoma of the ... ...
Abstract | Background: ENCORE, an observational, prospective, open-label study, investigated real-world treatment practices and outcomes with cetuximab plus platinum-based therapy (PBT) in first-line (1L) recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Aims: This multinational study aimed to investigate the long-term use of cetuximab plus PBT for 1L R/M SCCHN in a clinical setting. In particular, this study aimed to explore clinical considerations such as the decision to prescribe cetuximab plus PBT in R/M SCCHN, the mode and duration of treatment, and patient outcomes. Methods and results: Previously untreated patients with R/M SCCHN whose planned treatment was cetuximab plus PBT were enrolled from 6 countries. Among 221 evaluable patients, planned treatments included cetuximab plus carboplatin (31.2%), cisplatin plus 5-fluorouracil (31.7%), or carboplatin plus 5-fluorouracil (23.1%); 3.2% included a taxane, and 45.2% did not include 5-fluorouracil. Cetuximab treatment was planned for a fixed duration (≤24 weeks) in 15 patients (6.8%) and until disease progression in 206 (93.2%). Median progression-free survival and overall survival were 6.5 and 10.8 months, respectively. Grade ≥3 adverse events occurred in 39.8% of patients. Serious adverse events occurred in 25.8% of patients; 5.4% were cetuximab-related. Conclusion: In patients with R/M SCCHN, first-line cetuximab plus PBT was feasible and modifiable in a real-world setting with similar toxicity and efficacy as in the pivotal phase III EXTREME trial. Clinical trial registration number: EMR 062202-566. |
---|---|
Mesh-Begriff(e) | Humans ; Cetuximab/adverse effects ; Squamous Cell Carcinoma of Head and Neck/drug therapy ; Platinum/therapeutic use ; Carboplatin ; Prospective Studies ; Neoplasm Recurrence, Local/pathology ; Head and Neck Neoplasms/drug therapy ; Fluorouracil ; Cisplatin |
Chemische Substanzen | Cetuximab (PQX0D8J21J) ; Platinum (49DFR088MY) ; Carboplatin (BG3F62OND5) ; Fluorouracil (U3P01618RT) ; Cisplatin (Q20Q21Q62J) |
Sprache | Englisch |
Erscheinungsdatum | 2023-04-17 |
Erscheinungsland | United States |
Dokumenttyp | Observational Study ; Journal Article ; Research Support, Non-U.S. Gov't |
ISSN | 2573-8348 |
ISSN (online) | 2573-8348 |
DOI | 10.1002/cnr2.1804 |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.
Fernleihe an ZB MED
Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.